Abstract: The present invention relates to Brassica plants comprising mutant FAD2 genes, FAD2 nucleic acid sequences and proteins, as well as methods for generating and identifying said plants and alleles, which can be used to plants with increased levels of C18:1 in the seed oil. The invention further relates to combining the mutant FAD2 alleles with mutant FAD3 alleles to increase the levels of C18:1 and reduce the levels of C18:3 in the seed oil.

Abstract: The present invention relates to a method for modifying lateral budding in a plant comprising modifying the expression or function of a protein comprising the sequence shown as SEQ ID NO: 3, 4 or 5 or a sequence which has at least 70% sequence identity thereto. The invention further relates to plants, plant propagation material, harvested leaf and processed leaf obtainable by such methods.

Abstract: The present invention relates to a method for modifying lateral budding in a plant comprising modifying the expression or function of a protein comprising the sequence shown as SEQ ID NO: 1, 2, 7, 8 or a sequence which has at least 70% sequence identity thereto. The invention further relates to plants, plant propagation material, harvested leaf and processed leaf obtainable by such methods.

Abstract: Herbicide-detoxifying enzymes, compositions containing one or more of the enzymes, and plant seeds treated with the enzymes are provided. The enzymes can be used in methods for detoxifying auxin herbicides or degrading auxin plant regulators, including in methods for decontaminating surface of an apparatus used in agriculture or pesticide manufacturing, methods for decontaminating water, soil, soilless media, or sludge, and methods for protecting a plant from an auxin herbicide, improving a plant's tolerance to an auxin herbicide, or removing an auxin herbicide from the surface of a plant.

Abstract: Compositions and methods comprising polynucleotides and polypeptides having EPSP (5-enolpyruvylshikimate-3-phosphate) synthase (EPSPS) activity are provided. In specific embodiments, the sequence has an improved property, such as, but not limited to, improved catalytic capacity in the presence of the inhibitor, glyphosate. Further provided are nucleic acid constructs, plants, plant cells, explants, seeds and grain having the EPSPS sequences. Various methods of employing the EPSPS sequences are provided. Such methods include methods for producing a glyphosate tolerant plant, plant cell, explant or seed and methods of controlling weeds in a field containing a crop employing the plants and/or seeds disclosed herein.

Abstract: The invention provides recombinant DNA molecules and constructs, as well as their nucleotide sequences, useful for modulating gene expression in plants. The invention also provides transgenic plants, plant cells, plant parts, and seeds comprising the recombinant DNA molecules operably linked to heterologous transcribable DNA molecules, as are methods of their use.

Abstract: This disclosure concerns nucleic acid molecules and methods of use thereof for control of hemipteran pests through RNA interference-mediated inhibition of target coding and transcribed non-coding sequences in hemipteran pests. The disclosure also concerns methods for making transgenic plants that express nucleic acid molecules useful for the control of hemipteran pests, and the plant cells and plants obtained thereby.

Abstract: Methods and compositions for deploying refuge seeds together with transgenic crop seeds are provided. The refuge seeds can be non-transgenic seeds of a similar variety to that of the transgenic crop seeds, or the refuge seeds can be a transgenic variety, but in either case lacking a transgenic trait conferring pest protection found in the transgenic crop seeds.

Abstract: A method for producing a eukaryotic production cell line expressing a protein of interest (POI), comprising a) incorporating a gene of interest (GOI) encoding said POI into the chromosome of a eukaryotic host cell within an exogenous euchromatin protein expression locus by transfection, thereby obtaining a repertoire of recombinant host cells in a pool; b) selecting a single cell from said pool within 12 days after transfection, wherein selecting is at least according to the expression of said GOI or a marker indicating said expression; and c) isolating and expanding the selected single cell, thereby obtaining the production cell line.

Abstract: The present invention relates to a transgenic pig in which an immune rejection response is suppressed during xenotransplantation, wherein a gene coding for heme oxygenase-1 (HO-1) and a gene coding for tumor necrosis factor receptor 1-Fc (TNFR1-Fc) are simultaneously expressed and a gene coding for ?-1,3-galactosyltransferase (GGTA1) is knocked out; and a method for producing the same. The transgenic pig of the present invention, in which the genes coding for human HO-1 and TNFR1-Fc fusion protein are simultaneously expressed and the gene coding for GGTA1 is knocked out, may reduce oxidative stress during organ isolation and in vitro culture by antioxidative reaction, cytoprotective function, etc., and may also reduce a TNF-?-mediated inflammatory response in early transplantation by TNFR1-Fc expression.

Abstract: The present invention relates to a recombinant adeno-associated viral (r AAV) vector comprising neuropeptide Y (NPY) coding sequence and neuropeptide Y2 receptor (NPY2R) coding sequence. The invention further relates to a AAV particle comprising said vector, wherein the vector is encapsulated by adeno-associated virus (AAV) capsid proteins. Also, a pharmaceutical composition comprising said AAV particle, for use in the prevention or treatment of a neurological disorder in mammals, such as epilepsy.

Abstract: Adeno-associated virus rh.20 sequences, vectors containing same, and methods of use are provided.

Abstract: Provided herein are compositions and methods for selective expression of a transgene. Compositions and methods for selective expression of a transgene comprise one or more human regulatory elements, which, when operably linked to a transgene, can facilitate selective expression of a transgene (e.g., cell-type selective expression) in a target cell as compared to at least one or more non-target cells.

Abstract: Provided herein are compositions and methods for selective expression of a transgene. Compositions and methods for selective expression of a transgene comprise one or more human regulatory elements, which, when operably linked to a transgene, can facilitate selective expression of a transgene (e.g., cell-type selective expression) in a target cell as compared to at least one or more non-target cells.

Abstract: Provided herein are compositions and methods for selective expression of a transgene. Compositions and methods for selective expression of a transgene comprise one or more human regulatory elements, which, when operably linked to a transgene, can facilitate selective expression of a transgene (e.g., cell-type selective expression) in a target cell as compared to at least one or more non-target cells.

Abstract: Provided herein are compositions and methods for selective expression of a transgene. Compositions and methods for selective expression of a transgene comprise one or more human regulatory elements, which, when operably linked to a transgene, can facilitate selective expression of a transgene (e.g., cell-type selective expression) in a target cell as compared to at least one or more non-target cells.

Abstract: Nanostraws and to methods of utilizing them in order to deliver biologically relevant molecules such as DNA, RNA, proteins etc., into non-adherent cells such as immune cells, embryos, plant cells, bacteria, yeast etc. The methods described herein are repeatedly capable of delivering biologically relevant cargo into non-adherent cells, with high cell viability, dosage control, unaffected proliferation or cellular development, and with high efficiency. Among other uses, these new delivery methods will allow to scale pre-clinical cell reprogramming techniques to clinical applications.

Abstract: The present invention relates to methods for modifying the genome of a Bacillus host cell by employing a Class II Cas9 enzyme with only one active nuclease domain, e.g. the S. pyogenes Cas9 nickase, together with a suitable guide RNA for each target sequence to generate a site-specific nick in at least one genome target sequence followed by the repair of the nick(s) via integration of one or more modified modified donor part of the Bacillus host cell genome through classical double homologous recombination on each side of the nick(s).

Abstract: The present invention relates to a method of producing metal nanoparticles and metal sulfide nanoparticles using a recombinant microorganism co-expressing metallothionein and phytochelatin synthase, which are heavy metal-adsorbing proteins, and to the use of metal nanoparticles and metal sulfide nanoparticles synthesized by the method. The present invention provides a method for synthesizing metal nanoparticles which have been difficult to synthesize by conventional biological methods. The present invention makes it possible to synthesize metal nanoparticles in an environmentally friendly and cost-effective manner, and also makes it possible to synthesize metal sulfide nanoparticles. In addition, even metal nanoparticles which could have been produced by conventional chemical or biological methods are produced in a significantly increased yield by use of the method of the present invention.

Abstract: A fermentation process for producing magnesium lactate from a carbon source including the steps of: providing a fermentation medium including a fermentable carbon source in a fermentation reactor; fermenting the fermentation medium by a lactic acid producing microorganism in the presence of an alkaline magnesium salt to provide a fermentation broth including magnesium lactate; and recovering solid magnesium lactate from the magnesium lactate containing fermentation broth, wherein during at least 40% of the operating time of the fermentation process, the concentration of solid magnesium lactate in the fermentation broth is maintained in the range of 5-40 vol. %, calculated as solid magnesium lactate crystals on the total of the fermentation broth. The process allows stable operation at high productivity, in combination with efficient product separation.

Abstract: Presented herein are genetically engineered Pseudomonas strains capable of metabolizing ethylene glycol and producing polyhydroxyalkanoates.

Abstract: Methods for in situ amplification (ISA) of cfNA, such as cfDNA, in a sample are provided wherein the cfNA in the sample is not subject to a nucleic acid purification step. The methods disclosed may be used to generate an analyzable pool of cfNA present in the sample. The analyzable pool may be used with a variety of analytical techniques to characterize the nucleic acid in the sample. Methods of diagnosis, determining a therapeutic intervention and monitoring of a subject are also provided.

Abstract: Engineered 23S rRNAs and methods of use thereof for translation of proteins incorporating non-standard amino acids are provided. Typically, the 23S rRNA includes one or more mutations at positions 2496-2507 relative to E. coli wildtype 23S rRNA, wherein a ribosome composed of the 23S rRNA can catalyze the covalent transfer of a non-standard amino acid from an aminoacyl-RNA onto a nascent peptide chain. For example, the 23S rRNA can include the sequence UGACUU at positions 2502-2507 relative to E. coli wildtype 23S rRNA, and optionally the sequence AGCGUGA from positions 2057-2063 relative to E. coli wildtype 23S rRNA. The 23S rRNA can include additional or alternative deletions, substitutions, insertions, or combination thereof. The compositions and methods can be used to make polypeptides and sequence defined polymers.

Abstract: An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.

Abstract: Embodiments of the present disclosure relate to NADP-dependent oxidoreductase compositions, and electrodes, sensors and systems that include the same. Also provided are methods for making the compositions and for detecting and/or measuring analytes with NADP-dependent oxidoreductase compositions.

Abstract: Devices and methods capable of detecting glucose in saliva (FIG. 12). The devices feature a sensor having a substrate containing electrodes and one or more reagents on the electrodes. A detection device is operably coupled with the sensor to detect glucose based on measurement of an electrical parameter when electricity is applied to the electrode.

Abstract: Disclosed herein are compositions for assessing peptidoglycan biosynthesis in bacteria using modified dipeptides containing a bioorthogonal tag and applying novel post-labeling methods to label the bioorthogonal tag. The resultant, labeled peptidoglycan structures are amenable for identifying bacteria by microscopic visualization.

Abstract: Apparatuses and associated methods are described for the efficient evaluation of C1-containing substrates, and especially for such evaluation conducted locally, or on-site, at a prospective facility for implementation of a biological conversion process for desired end product using a C1 carbon source. The exact composition of a given, industrial C1-containing substrate, as well as the range in composition fluctuations, are generally difficult to reproduce at a remote facility (e.g., a laboratory or a pilot-scale or demonstration-scale process), as required for the accurate prediction/modeling of commercial performance to justify large capital expenditures for commercial scale-up.

Abstract: The present invention relates to a method for rapid detection of toxicity comprising preparing a plant gel agar and a sample; mixing the agar gel with the sample to form a mixture; and measuring a coagulation time of the mixture to determine the cytotoxicity of the sample.

Abstract: Disclosed herein are compositions for assessing peptidoglycan biosynthesis in bacteria, for identifying bacteria, and for screening for bacterial cell wall-acting and/or cell wall-disrupting agents via modified D-amino acids and methods of use thereof. Also disclosed are live bacteria having one or more modified D-amino acids as described herein incorporated into peptidoglycan of a bacterial cell wall.

Abstract: The purpose of the present invention is to provide a detection means whereby Staphylococcus aureus can be identified at a high accuracy. An aspect of the present invention relates to a medium for detecting S. aureus which comprises one or more kinds of nutrient components, a color developing agent capable of developing a color in the presence of ?-glucosidase, a color developing agent capable of developing a color in the presence of phosphatase and 0.5 mg/cm3 or more of sodium colistin methanesulfonate. Another aspect of the present invention relates to a sheet for detecting S. aureus, said sheet comprising the aforesaid medium, and a method for detecting S. aureus with the use of the medium and sheet as described above.

Abstract: A steam sterilization indicator for indicating acceptability of a sterilization cycle includes a temperature indicator for indicating the temperature used in the sterilization cycle.

Abstract: The present invention relates to a method for measuring activity of HAO which comprises bringing HAO into contact with hydroxylamine in the presence of a tetrazolium salt. Further, the present invention also provides a method for culturing microorganisms which comprises culturing microorganisms in a storage container of a sample containing microorganisms installed separately in a liquid medium storage container, wherein the storage container of a sample containing microorganisms has pores.

Abstract: Embodiments of the invention include methods of identifying microorganisms and/or diagnosing infections in subjects cause by microorganisms. Embodiments of the invention may also include further characterizing (e.g., determining the presence of one or more antibiotic resistance markers) the microorganisms and determining a strain identity of the microorganisms.

Abstract: The present disclosure provides improved methods for isolating asymmetrically-primed and/or asymmetrically-tagged nucleic acid complexes that find use in downstream analytical analyses, including sequence analysis. Compositions comprising such complexes and kits and systems for generating such complexes are also provided.

Abstract: Certain embodiments provide a method for capturing a genomic fragment. The method may comprise: obtaining a substrate comprising a first population of surface-bound oligonucleotides and a second population of surface-bound oligonucleotides; hybridizing a first member of the first population of surface-bound oligonucleotides to a selection oligonucleotide comprising a region that hybridizes with the first member and a region that contains a genomic sequence; extending the first member of the first population of surface-bound oligonucleotides to produce a support-bound selection primer that comprises a sequence that is complementary to the genomic sequence; hybridizing the support-bound selection primer to a nucleic acid fragment comprising the genomic sequence; extending the support-bound selection primer to produce an extension product that contains a sequence that flanks the genomic sequence, e.g., in a genome; and amplifying the extension product on the substrate.

Abstract: A pretreatment kit includes a container (10) for particle manipulation, nucleic acid capture particles (70) capable of selectively binding to nucleic acid, aqueous-phase separation medium (21, 22, 23), a plurality of kinds of aqueous liquids (35, 31, 32, 38), and a nucleic acid for individual identification. The nucleic acid for individual identification is contained in at least one of the plurality of kinds of aqueous liquids or is bound onto the surfaces of the nucleic acid capture particles. The base sequence of the nucleic acid for individual identification contains an identification sequence including a base sequence noncomplementary to the nucleic acids contained in the biological sample. The pretreatment kit is used for separating nucleic acids from biological samples that contains nucleic acids and contaminants.

Abstract: Provided herein are methods of detecting nucleic acids. The nucleic acid of interest may be detected by using Cas endonuclease to degrade substantially all nucleic acid in a sample except for the nucleic acid of interest, leaving the nucleic acid of interest isolated and amenable to detection. In related methods, Cas endonuclease complexes are used to protect the nucleic acid of interest while unprotected nucleic acid is digested, e.g., by exonuclease, after which the isolated nucleic acid of interest is detected.

Abstract: Methods of making a three-dimensional matrix of nucleic acids within a cell is provided.

Abstract: Provided herein are methods and composition for immune repertoire sequencing and single cell barcoding. The methods and compositions can be used to pair any two sequences originating from a single cell, such as heavy and light chain antibody sequences, for antibody discovery, disease and immune diagnostics, and low error sequencing.

Abstract: The present invention relates to a novel method for an accurate quantification in intestinal samples of Faecalibacterium prausnitzii phylogroup I members (PHGI) and/or Faecalibacterium prausnitzii phylogroup II members (PHGII). It further relates to a method for detecting intestinal diseases, including the screening, diagnosis, differential diagnosis, and/or monitoring of disease activity or progression in a human subject comprising determining the abundance of PHGI and/or PHGII in an intestinal sample from said subject. Moreover, it relates to a method for the prediction of the efficacy of a drug in the therapeutic treatment of an intestinal disease in a human subject comprising determining the abundance of PHGI and/or PHGII in an intestinal sample from said subject.

Abstract: The disclosed invention include nucleic acid oligomers that may be used as amplification oligomers, including primers, as capture probes for sample preparation, and detection probes for detection of 16S rRNA from Atopobium vaginae in samples by using methods of specific nucleic acid amplification and detection.

Abstract: The present application describes a biosensor for detecting target nucleic acid. The biosensor's mode of operation is based on binding of the target nucleic acid to another nucleic acid sequence and a circular template which triggers rolling circle amplification and detection of the amplified product as the indicator of the presence of the target nucleic acid. The biosensor is immobilized on a solid support, such as paper.

Abstract: Systems and methods for detecting copy number variations, chromosomal abnormalities, exonic deletions or duplications, or other genetic variations using molecular inversion probes and probe capture metrics.

Abstract: The invention pertains to an assay that is capable of detecting a mutant polynucleotide in a plurality of polynucleotides. In one embodiment, the assay of the invention is capable of detecting one copy of a mutant polynucleotide in about 50,000 to about 100,000 copies of polynucleotides. The assay of the invention can be used to identify a mutant viral quasispecies or a mutant mRNA encoding an oncogenic protein from a tumor sample. The assay of the invention involves producing the single stranded complements of each of a plurality of polynucleotides containing the target sequence, wherein each of the single stranded complements contain a unique tag sequence and amplifying the single stranded complements by PCR using several sets of primers designed to introduce the sequences appropriate for a paired-end sequencing analysis of the amplified polynucleotides. The invention also pertains to kits for carrying out the assays of the invention.

Abstract: The invention provides a method of karyotyping (for example for the detection of trisomy) a target cell to detect chromosomal imbalance therein, the method comprising: (a) interrogating closely adjacent biallelic SNPs across the chromosome of the target cell (b) comparing the result at (a) with the SNP haplotype of paternal and maternal chromosomes to assemble a notional haplotype of target cell chromosomes of paternal origin and of maternal origin (c) assessing the notional SNP haplotype of target cell chromosomes of paternal origin and of maternal origin to detect aneuploidy of the chromosome in the target cell. Also provided are related computer-implemented embodiments and systems.

Abstract: Methods are disclosed for identifying antibacterial compounds which inhibit propagation of selected spectrum bacteria, which bacteria use specific tRNA to code for Ala, Met, Ser, or Leu that other bacteria do not use. In one embodiment, the selected spectrum bacteria use GCA to code for Ala, whereas other bacteria use a different codon to code for alanine. The methods involve determining whether putative inhibitors promote or inhibit complex formation between the tRNA and a bacterial ribosome, or between the tRNA and an aminoacyl synthetase. Compounds which promote or inhibit complex formation can disrupt protein production, which bacteria need to propagate. The identified antibacterial compounds can selectively inhibit bacterial propagation. By limiting their effects to the selected spectrum bacteria, these compounds can treat or prevent specific bacterial infections without disrupting the normal bacterial flora, the patients' microbiome, or causing antibacterial resistance.

Abstract: Localized detection of RNA in a tissue sample that includes cells is accomplished on an array. The array includes a number of features on a substrate. Each feature includes a different capture probe immobilized such that the capture probe has a free 3? end. Each feature occupies a distinct position on the array and has an area of less than about 1 mm2. Each capture probe is a nucleic acid molecule, which includes a positional domain including a nucleotide sequence unique to a particular feature, and a capture domain including a nucleotide sequence complementary to the RNA to be detected. The capture domain can be at a position 3? of the positional domain.

Abstract: Localized detection of RNA in a tissue sample that includes cells is accomplished on an array. The array include a number of features on a substrate. Each feature includes a different capture probe immobilized such that the capture probe has a free 3? end. Each feature occupies a distinct position on the array and has an area of less than about 1 mm2. Each capture probe is a nucleic acid molecule, which includes a positional domain including a nucleotide sequence unique to a particular feature, and a capture domain including a nucleotide sequence complementary to the RNA to be detected. The capture domain can be at a position 3? of the positional domain.

Abstract: The present invention describes methods for performing higher multiplexed real-time PCR for detection and quantitation of target nucleic acids using TAGS hydrolysis probes.